Poland· PL-100354887
Respreeza
A alfa1 antitrypsin product containing inhibitor alfa-1 proteinazy, ludzki, registered in Poland by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Alfa1 antitrypsin is registered in 11 of 19 countries.
Countries holding a registration under ATC B02AB02 (alfa1 antitrypsin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Alfa1 antitrypsin · ATC B02AB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of alfa1 antitrypsin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alfa1 antitrypsin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$261.83
The record
At a glance
URPL (Poland)- Active substance
- Inhibitor alfa-1 proteinazy, ludzki
- Manufacturer
- CSL Behring GmbH
- Country
- Poland (PL)
- ATC code
- B02AB02
- ATC class
- Alfa1 antitrypsin
- Defined daily dose
- 0.6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991245702
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alfa1 antitrypsin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandProlastinaGrifols Deutschland GmbH
- NorwayProlastinaGrifols Deutchland GmbH
- SwedenProlastina 1000 mg Pulver och vätska till infusionsvätska, lösningGrifols Deutschland GmbH
- FranceALFALASTIN 33,33 mg/mL, poudre et solvant pour solution injectableLFB-BIOMEDICAMENTS
- CzechiaPROLASTINAGrifols Deutschland GmbH, Frankfurt
- IcelandRespreezaCSL Behring GmbH*
- IrelandProlastin 4000 mg, powder and solvent for solution for infusionGrifols Deutschland GmbH
- United StatesGLASSIATakeda Pharmaceuticals America, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Prolastin
- Belgium · Pulmolast
- Cyprus · Prolastina
- Czechia · Prolastina
- Germany · Prolastin
- Denmark · Prolastina
- Spain · Prolasplan, Prolastina
- Finland · Prolastina
- France · Alfalastin, Prolastin
- Greece · Prolastin
- Croatia · Prolastina
- Ireland · Prolastin
- Iceland · Respreeza
- Italy · Plitalfa, Prolastin
- Liechtenstein · Respreeza
- Netherlands · Prolastin
- Norway · Prolastina, Respreeza
- Portugal · Prolastin
- Sweden · Prolastina
- Slovakia · Prolastina
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/02f6f3cd-c4a1-4a06-ac77-4a696df6f9cf GET /v1/drugs/02f6f3cd-c4a1-4a06-ac77-4a696df6f9cf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "1000 mg",
"packaging": "05909991245702 ¦ Rpz ¦ EU/1/15/1006/001 ¦ 111179\n1 fiol. proszku ¦ 1 fiol. 20 ml rozp. ¦ 1 zestaw do transferu",
"substance": "alfa-1-Proteinasi inhibitor humanus 1000 mg",
"common_name": "Inhibitor alfa-1 proteinazy, ludzki",
"pl_product_id": "100354887",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about alfa1 antitrypsin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.